Parameter
| Biomarker | IL-6 | Full name | Interleukin-6 | Molecular Type | Protein（Cytokine） |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis、Prediction of treatment response |
| Disease | Renal Cell Carcinoma(RCC) | Disease Subtypes | / | ||
| Organ | Kidney | Test Sample / Technology Platform | Serum（ELISA） | ||
| Pathobiological Mechanisms | RCC cells secrete under hypoxic conditions to promote tumor progression and inflammatory response | ||||
| Clinical Availability Status | Study test/clinical exploration: Prognostic potential of pazopanib demonstrated in prospective study | ||||
| Notes and Dynamics | Patients with elevated IL-6 levels benefit more significantly from pazopanib treatment; this has greater prognostic value than clinical staging | ||||